Lending support to his choice, Barclays analyst Lauren Lieberman, on May 21, maintained Coca-Cola with an Overweight rating and raised the price target from $85 to $89.Don't forget to check out our premarket coverage hereBill Baruch, founder and CIO of both Blue Line Capital, an investment advisor, and Blue Creek Capital Management, picked AbbVie Inc. (NYSE:ABBV).As per the recent news, AbbVie, on May 29, announced European Commission authorization of expanded label for VENCLYXTO® (venetoclax) to include additional combinations in previously untreated chronic lymphocytic leukemia.Jenny Van Leeuwen Harrington, chief executive officer of Gilman Hill Asset Management, LLC, recommended Sabra Health Care REIT, Inc. (NASDAQ:SBRA).On the earnings front, Sabra Health Care, on April 29, posted better-than-expected results for the first quarter.Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, named UnitedHealth Group Incorporated (NYSE:UNH) as his final trade.Supporting his view, B of A Securities analyst Kevin Fischbeck, on June 4, upgraded UnitedHealth Group from Neutral to Buy and raised the price target from $420 to $450.Price Action:
Coca-Cola shares gained 3.5% to close at $79.48 on Friday.
